BiomX Inc. (PHGE): Price and Financial Metrics
PHGE Price/Volume Stats
Current price | $0.51 | 52-week high | $8.55 |
Prev. close | $0.58 | 52-week low | $0.50 |
Day low | $0.50 | Volume | 103,700 |
Day high | $0.58 | Avg. volume | 110,983 |
50-day MA | $0.89 | Dividend yield | N/A |
200-day MA | $2.43 | Market Cap | 9.25M |
PHGE Stock Price Chart Interactive Chart >
BiomX Inc. (PHGE) Company Bio
BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
PHGE Price Returns
1-mo | -45.74% |
3-mo | -62.88% |
6-mo | -85.00% |
1-year | -88.67% |
3-year | -97.27% |
5-year | -99.35% |
YTD | -81.79% |
2023 | 49.97% |
2022 | -88.33% |
2021 | -74.92% |
2020 | -34.12% |
2019 | N/A |
Loading social stream, please wait...